Trial
NCT04140305
Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Celgene
Collaborators
—
Condition
Multiple Sclerosis
Intervention
RPC-1063
Why stopped
Business objective has changed
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-06-12